Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 477 publications
Integrating oral pre-exposure prophylaxis delivery in primary care family planning clinics: a pragmatic, stepped-wedge, cluster-randomised trial.
Journal: The Lancet. Primary care
Published: June 03, 2026
HIV acquisitions, safety, and pharmacokinetics of lenacapavir for HIV pre-exposure prophylaxis in pregnant and lactating women (PURPOSE 1): a substudy of a phase 3, randomised controlled trial.
Journal: The lancet. HIV
Published: April 10, 2026
Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study.
Journal: Annals of internal medicine
Published: December 22, 2025
Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 study.
Journal: The Lancet. Microbe
Published: September 12, 2025
Effect of enhanced peer PrEP referral with HIV self-testing delivery among young Kenyan women: A randomized controlled trial of peer networks.
Journal: PLoS medicine
Published: July 02, 2025
Trichomonas vaginalis Among Cisgender Women Taking Doxycycline Postexposure Prophylaxis.
Journal: The Journal of infectious diseases
Published: April 28, 2025
Adherence thresholds for emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis against HIV acquisition in cisgender women: A randomized directly observed dosing study.
Journal: PLoS medicine
Published: February 17, 2025
Understanding barriers and facilitators to doxycycline post-exposure prophylaxis adherence among young women in western kenya: a qualitative study.
Journal: BMC infectious diseases
Published: February 03, 2025
Lenacapavir for HIV Prevention: A Commitment to Equitable Access and Partnership by Gilead Sciences.
Lenacapavir for HIV Prevention: A Commitment to Equitable Access and Partnership by Gilead Sciences.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: December 14, 2024
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons.
Journal: The New England journal of medicine
Published: November 27, 2024
Understanding the sources of efficacy dilution in a trial of a monthly dapivirine vaginal ring for HIV-1 prevention.
Journal: International journal of STD & AIDS
Published: November 26, 2024
Non-communicable disease (NCD) risk among people living with HIV in KwaZulu-Natal, South Africa: evidence from a randomised trial of community-based differentiated service delivery.
Journal: Journal of the International AIDS Society
Published: October 22, 2024
Last Updated: 09/26/2026